BCL11A Polymorphism in Egyptian Children with β-Thalassemia: Relation to Phenotypic Heterogeneity

Abstract

Fetal hemoglobin (HbF) is a potent genetic modifier of β-thalassemia phenotype. B-cell lymphoma 11A (BCL11A) gene results in significant silencing of HbF. The aim of this study was to assess the prevalence of different BCL11A genotypes among a cohort of Egyptian children with β-thalassemia and to correlate them to HbF and clinical severity score. Eighty-two children with β-thalassemia (aged 12.95 ± 3.63 years) were recruited from the Pediatric Hematology Clinic, Ain Shams University. They were divided based on the clinical severity of β-thalassemia into three subgroups: 20 mild (24.4%), 24 moderate (29.3%), and 38 severe (46.3%). Age, gender, age of diagnosis, initial HbF level, transfusion history, and history of splenectomy were assessed. Anthropometric measures, signs of anemia and hemosiderosis, and the severity score were determined. Laboratory investigations such as complete blood picture, ferritin, and single gene polymorphism genotyping of the rs11886868 were also performed. Our findings showed that 16 children had CC genotype (19.5%), 38 had TC genotype (46.3%), and 28 had TT genotype (34.1%) of the rs#. β-thalassemia children with TT genotype had significantly higher severity scoring than the other two groups (p < 0.001). Moreover, mean initial HbF was found to be lower in children with TT genotype followed by TC and CC genotypes (p < 0.001). Increased γ-globin expression associated with BCL11A gene polymorphism is associated with better clinical severity of β-thalassemia.

Keywords

BCL11A polymorphism - β-thalassemia - phenotypic heterogeneity

Publikationsverlauf

Eingereicht: 23. Dezember 2020

Angenommen: 10. März 2021

Artikel online veröffentlicht:
01. Juni 2021

• References

• 1 Giardine B, Borg J, Viennas E. et al. Updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Res 2014; 42 (Database issue): D1063-D1069
• 2 Akhtar MS, Qaw F, Borgio JF. et al. Spectrum of α-thalassemia mutations in transfusion-dependent β-thalassemia patients from the Eastern Province of Saudi Arabia. Hemoglobin 2013; 37 (01) 65-73
• 3 Dadheech S, Madhulatha D, Jainc S, Joseph J, Jyothy A, Munshi A. Association of BCL11A genetic variant (rs11886868) with severity in β-thalassaemia major & sickle cell anaemia. Indian J Med Res 2016; 143 (04) 449-454
• 4 Thein SL. Genetic basis and genetic modifiers of β-thalassemia and sickle cell disease. Adv Exp Med Biol 2017; 1013: 27-57
• 5 Graffeo L, Vitrano A, Giambona A. et al. The heterozygote state for β-thalassemia detrimentally affects health outcomes. Am J Hematol 2017; 92 (03) E23-E25
• 6 Li J, Lai Y, Shi L. BCL11A down-regulation induces γ-globin in human β-thalassemia major erythroid cells. Hemoglobin 2018; 42 (04) 225-230
• 7 Liu N, Hargreaves VV, Zhu Q. et al. Direct promoter repression by BCL11A controls the fetal to adult hemoglobin switch. Cell 2018; 173 (02) 430-442.e17
• 8 Yin J, Xie X, Ye Y, Wang L, Che F. BCL11A: a potential diagnostic biomarker and therapeutic target in human diseases. Biosci Rep 2019; 39 (11) BSR20190604
• 9 Rachmilewitz EA, Giardina PJ, Patricia JG. How I treat thalassemia. Blood 2011; 118 (13) 3479-3488
• 10 Munkongdee T, Chen P, Winichagoon P, Fucharoen S, Paiboonsukwong K. Update in laboratory diagnosis of thalassemia. Front Mol Biosci 2020; 7: 74
• 11 Piomelli S, Graziano J, Karpatkin M. et al. Chelation therapy, transfusion requirement, and iron balance in young thalassemic patients. Ann N Y Acad Sci 1980; 344: 409-417
• 12 Cappellini MD, Cohen A, Eleftheriou A. et al. Blood transfusion therapy in β-thalassaemia major. In: Guidelines for the Clinical Management of Thalassaemia [Internet]. 2nd revised ed. Chap 2. Nicosia (CY): Thalassaemia International Federation; 2008. . Chapter 2
• 13 Graziano JH, Piomelli S, Hilgartner M. et al. Chelation therapy in beta-thalassemia major. III. The role of splenectomy in achieving iron balance. J Pediatr 1981; 99 (05) 695-699
• 14 Sripichai O, Makarasara W, Munkongdee T. et al. A scoring system for the classification of beta-thalassemia/Hb E disease severity. Am J Hematol 2008; 83 (06) 482-484
• 15 Sankaran VG, Xu J, Ragoczy T. et al. Developmental and species-divergent globin switching are driven by BCL11A. Nature 2009; 460 (7259): 1093-1097
• 16 Sankaran VG, Menne TF, Xu J. et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008; 322 (5909): 1839-1842
• 17 Menzel S, Garner C, Gut I. et al. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet 2007; 39 (10) 1197-1199
• 18 Neishabury M, Zamani F, Keyhani E. et al. The influence of the BCL11A polymorphism on the phenotype of patients with beta thalassemia could be affected by the beta globin locus control region and/or the Xmn1-HBG2 genotypic background. Blood Cells Mol Dis 2013; 51 (02) 80-84
• 19 Galanello R, Sanna S, Perseu L. et al. Amelioration of Sardinian beta0 thalassemia by genetic modifiers. Blood 2009; 114 (18) 3935-3937
• 20 Database of Single Nucleotide Polymorphisms (dbSNP). National Center for Biotechnology Information, National Library of Medicine. (dbSNP Build ID: {rs766432, rs11886868, rs9399137}). Accessed March 9, 2016 at: http://www.ncbi.nlm.nih.gov/SNP/2015
• 21 Danjou F, Anni F, Perseu L. et al. Genetic modifiers of β-thalassemia and clinical severity as assessed by age at first transfusion. Haematologica 2012; 97 (07) 989-993
• 22 Cantor AB, Orkin SH. Transcriptional regulation of erythropoiesis: an affair involving multiple partners. Oncogene 2002; 21 (21) 3368-3376
• 23 Cao H, Stamatoyannopoulos G, Jung M. Induction of human gamma globin gene expression by histone deacetylase inhibitors. Blood 2004; 103 (02) 701-709
• 24 Bauer DE, Kamran SC, Lessard S. et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science 2013; 342 (6155): 253-257
• 25 Galarneau G, Palmer CD, Sankaran VG, Orkin SH, Hirschhorn JN, Lettre G. Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation. Nat Genet 2010; 42 (12) 1049-1051
• 26 Rujito L, Basalamah M, Siswandari W. et al. Modifying effect of XmnI, BCL11A, and HBS1L-MYB on clinical appearances: a study on β-thalassemia and hemoglobin E/β-thalassemia patients in Indonesia. Hematol Oncol Stem Cell Ther 2016; 9 (02) 55-63
• 27 Wilber A, Nienhuis AW, Persons DA. Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities. Blood 2011; 117 (15) 3945-3953